Overview

Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function

Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
0
Participant gender:
All
Summary
1. Ticagrelor inhibits inflammation and improves vascular endothelial cell function to a greater extent than clopidogrel in ST-segment elevation myocardial infarction(STEMI) patients receiving percutaneous coronary intervention. 2. Ticagrelor can reduce the serum levels of inflammatory biomarkers both in coronary and in peripheral venous in patients with ST-segment elevation myocardial infarction(STEMI).
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Jinan Central Hospital
Treatments:
Clopidogrel
Ticagrelor
Ticlopidine
Criteria
Inclusion Criteria:

1. Male or non-pregnant female.

2. Age ≥ 18 years old and <80 years old.

3. Consecutive patients who should be hospitalized with documented evidence of ST-Segment
Elevation Myocardial Infarction receiving Percutaneous Coronary Intervention.

4. All patients havepersistent≥0.2 Millivolt ST segment elevation in two or more
contiguous precordial leads or ≥0.1 Millivolt ST elevation in two or more contiguous
limb leads, with one of the following: persistent chest pain or elevatory of
biomarkers of myocardial necrosis.

5. Time from chest pain onset to receiving Percutaneous Coronary Intervention <12 hours.

6. Persistent chest pain <12 hours.

7. Provision of informed consent prior to any study specific procedures.

Exclusion Criteria:

1. Involved in other trials.

2. In recent one year have P 2 Y 12 receptor antagonist drug treatment history or
long-term use of immunosuppressive agents.

3. Recurrent myocardial infarction or previous history of Coronary Artery Bypass
Graft(CABG) surgery or rescue Percutaneous Coronary Intervention.

4. Active bleeding or bleeding history.

5. With obvious infection and body temperature (axillary temperature) higher than 38.0 ℃.

6. Autoimmune diseases.

7. Malignancies.

8. In recent 6 months have received major surgery.

9. Left ventricular ejection fraction is less than 30%.

10. Life expectancy less than one year.

11. With moderate and severe liver function deterioration.

12. End-stage renal failure.

13. Other conditions that may put the patient at risk or influence study results in the
investigators' opinion:eg, increased risk of bradycardiac events; known clinically
important thrombocytopenia; known clinically important anemia; severe hemodynamic
instability.

14. Other contraindications to investigate products.

15. Any condition that increases the risk for noncompliance or being lost to follow-up.